p160 coregulators were initially identified as nuclear hormone receptor coactivators. In this study, functional data demonstrate that members of the three p160 families can have opposing roles in regulating gene expression by the same transcription factor. Both SRC1A and p/CIP function as coactivators for MyoD-mediated transcription whereas GRIP1 acts negatively as a (co)repressor. SRC1A and p/CIP predominantly interact with distinct sites on the NH 2 -terminal activation domain of MyoD. GRIP1 binds to both these regions but it alone, and neither SRC1A nor p/CIP, also interacts with specific sites on MyoD that are critical for the binding of the essential MyoD coactivator, p300. This suggests that competition by GRIP1 for SRC1A, p/CIP, and p300 binding sites on a transcription factor may regulate the activity of the factor.
When they were initially discovered, the p160 proteins were thought to act only as coactivators of nuclear hormone receptormediated transcription in a ligand-dependent manner (for review, see Refs. [1] [2] [3] [4] [5] . However, evidence rapidly accumulated to suggest that their functions are not limited to interactions with nuclear receptor-activated transcription but extended to potentiation of other transcriptional activators, e.g. Sp1 (6), NFB (7) (8) (9) , serum response factor (SRF) (10), AP1 (11) , CREB (12) , and STAT-1 (12) . All three classes of the p160 family of proteins, represented by SRC1A (6, (13) (14) (15) , GRIP1 (15) (16) (17) , and p/CIP (15, 18 -21) , also associate with the coactivator p300/ CBP (13, 15, (22) (23) (24) and the coactivator pCAF (12, 18, 25) .
We have been investigating the mechanisms of regulation of the myogenic transactivator MyoD and its requirements for p300 and PCAF (26 -30) . Because of these shared characteristics of MyoD-mediated transactivation and the known mechanisms of p160 coactivation we inferred that the p160 proteins might well act as myogenic coregulators through direct interactions with MyoD transcriptional complexes.
Here we present functional data showing that representatives of each of the three classes of p160s do not always act in concert but can have opposing roles in regulating gene expression by the same transcription factor. Whereas both SRC1A and p/CIP indeed function as coactivators for MyoD-mediated transcription, GRIP1 surprisingly acts in an opposite manner and serves as a (co)repressor, the first example of such negative activity. We identified the domains of MyoD that are essential for physically and functionally interacting with each of the p160 proteins. SRC1A and p/CIP predominantly interact with distinct sites on the NH 2 -terminal activation domain of MyoD. GRIP1 binds to both these regions, but it alone, and neither SRC1A nor p/CIP, also interacts with specific sites on MyoD that are critical for the binding of the essential MyoD coactivator, p300. This suggests that competition by GRIP1 for SRC1A, p/CIP, and p300 binding sites on a transcription factor might regulate the activity of the factor.
EXPERIMENTAL PROCEDURES
Plasmids-The cDNAs for GRIP1 and p/CIP generously provided by M. Stallcup (University of Southern California) and M. Rosenfeld (University of California, San Diego, CA) and the cDNA for SRC1A (31) were subcloned into pSG5 (Stratagene). pSG5GRIP1 was kindly provided by M. Stallcup (University of Southern California). 4RELUC, MCKLUC, and pCDNA3MyoD have been described previously (26 -28) . HCALUC was made by substituting the chloramphenicol acetyltransferase (CAT) 1 cassette of HCACAT with a luciferase (LUC) cassette derived from pGL2-Basic (Promega). pCDNA3MyoDflag has been described previously (26) . The cDNAs for GRIP1, SRC1A, and p/CIP were subcloned into pCMX-Gal4N (a gift from R. Evans, Salk Institute) or pCMX-LexA, respectively. pCMX-LexA was made by substituting the Gal4 DNA binding domain of pCMX-Gal4N with the LexA DNA binding domain of pEG202 (a gift from E. Golemis, Fox Chase Cancer Center). L8G5LUC was generously provided by S. Hollenberg (Volum Institute). G4TATALUC was made by cleaving out a 17-mer-TATA fragment from a 17-TATA poly(A) vector (generous gift of Ming-Jer Tsai, Baylor) and subcloning it into pGL2-Basic. GST-MyoD was originally provided by H.
Weintraub (Hutchinson Cancer Institute). pCMXVP16MyoD was made by subcloning PCR amplified MyoD fragment into pCMXVP16 (a gift from R. Evans, Salk Institute). Various deletions as well as site-specific mutants of GST-MyoD were created by subcloning different PCR amplified DNA fragments into pGEX2TK. Each set of deletion mutants of GRIP1, SRC1A, p/CIP, as well as Gal4DBD fusion constructs were made by subcloning various PCR amplified DNA fragments into either pSG5, pCDNA3, or pCMX-Gal4N expression vectors. The nucleotide sequences of all the mutants have been determined at least for the critical regions subjected to changes. All the expression vectors, either prokaryotic or eukaryotic, were tested for production of a protein of the expected molecular size determined either by Coomassie Blue staining for bacterially produced proteins or in vitro translation for proteins expressed in mammalian cells.
Cell Culture, Transient Transfections, and Luciferase Reporter Assays-Mouse C3H10T1/2 embryo fibroblasts obtained from the American Type Culture Collection were maintained in Dulbecco's modified Eagle's medium supplemented with fetal bovine serum (10% fetal bovine serum, heat-inactivated). Transient transfections were carried out by the BES-buffered saline method as described (26) . When cells reached ϳ40 -60% confluence, plasmid DNA (total of 9 g per 60 mm-diameter dish) was added as a calcium phosphate precipitate. The medium was replenished 16 -20 h later. Luciferase assays were carried out after an additional 48 h of incubation for the transfected 10T1/2 cells following the manufacturer's protocol. All luciferase assays were done either in duplicate or triplicate with each of two to three independent plasmid preparations. All results were normalized to total protein in cell lysates.
Both SRC1Aϩ/ϩ and SRC1AϪ/Ϫ mouse embryonic fibroblasts (MEFs) (31) were maintained in Dulbecco's modified Eagle's medium supplemented with fetal bovine serum (10%) and ␤-mercaptoethanol (10 Ϫ4 M). MEFs were refed with fresh medium without 2-mercaptoethanol when transient transfections were carried out. To measure the transcription activity of MyoD in SRC1AϪ/Ϫ MEFs, 4RELUC, MCK-LUC, or HCALUC (1 g each) reporter, plus pCDNA3MyoD expression vectors (amounts as shown in the figures), were cotransfected into the MEFs.
In Vitro Protein-Protein Interaction Assays-In vitro transcriptiontranslation was carried out using 1 g of various supercoiled DNA plasmids, TNT® coupled transcription/translation system (Promega), and L-[ S]methionine (Ͼ1000 Ci/mmol; Amersham Biosciences) according to the manufacturer's protocol. The expression and purification of various glutathione S-transferase (GST) fusion proteins as well as protein-protein interaction assays were performed as described previously (26 -28) with slight modifications. The GST and GST fusion proteins were expressed in Escherichia coli (BL21) and purified using glutathione-agarose affinity matrix (Sigma). The molecular weight of each individual purified protein was analyzed and confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Normalized amounts of agarose-bound GST fusion proteins were incubated with 10 l of [
35 S]methionine-labeled translation products in NETN binding buffer (Nonidet P-40, 0.5%; EDTA, 1 mM; Tris-HCl, 20 mM, pH 8.0; NaCl, 100 mM; ethidium bromide, 12.5 g) at 4°C for 1 h. The beads were washed three times with iced NETN, and the bound proteins were released by incubating at 95°C for 3 min. The released proteins were then analyzed on 10% SDS-PAGE. The gels were then fixed (H 2 O, 50%; methanol, 40%; acetic acid, 10%; 20 min), treated with Enlightning™ (DuPont, 20 min), dried, and subjected to autoradiography.
RESULTS

GRIP1
Represses MyoD on Muscle-specific Promoters-We first investigated the effects of p160s on MyoD dependent transcription using muscle-specific promoters fused to a reporter gene. 4RELUC contains four tandem E-box motifs and is activated only by MyoD family members but not other myogenic activators. MCKLUC and HCALUC carry the muscle specific regulatory enhancers of the muscle creatine kinase gene and the human cardiac ␣-actin gene, respectively. Mouse CH310T1/2 fibroblasts were transiently transfected with one of the reporters plus an expression vector for MyoD and for a p160 protein (Fig. 1) .
As expected, MyoD alone specifically activates all three promoters ( Fig. 1, A-C) . Importantly, both SRC1A and CIP were capable of potentiating MyoD transactivation on all three promoters, establishing them as coactivators of MyoD. Very surprisingly, however, GRIP1 not only failed to increase MyoDmediated induction of reporter activity but repressed it strongly on all three promoters (and nearly completely on the 4RELUC and MCKLUC promoters). Similar effects on MyoDdependent transcription by p160s also occurs in C2C12 myoblasts and in differentiated C2C12 myotubes. 2 These results strongly imply that SRC1A and p/CIP function in myogenic cells as positive regulators for MyoD, whereas GRIP1 acts negatively in both myogenically undifferentiated and differentiated cells. Furthermore, that these effects are seen using the 4RELUC reporter supports the notion that the effects are mediated through direct interactions with MyoD and not secondarily through effects on other myogenic transcription factors.
The Transactivation Activity of MyoD Is Diminished In SRC1AϪ/Ϫ Mouse Embryonic Fibroblasts-We used SRC1AϪ/Ϫ MEFs derived from the SRC1AϪ/Ϫ mice to test whether SRC1A is essential for MyoD transactivation of muscle-specific promoters. We compared the ability of MyoD to transactivate the target reporters in wild type versus SRC1AϪ/Ϫ MEFs. As shown in Fig. 2 , the MyoD-dependent reporter activity was many fold less on the 4RE promoter ( Fig. 2A) , the muscle creatine kinase (MCK) promoter ( Fig. 2B) , and on the human cardiac ␣-actin (HCA) promoter ( Fig. 2C ) in the SRC1AϪ/Ϫ MEFs. Indeed, the activation of the muscle creatine kinase promoter mediated by MyoD was completely silenced in the SRC1AϪ/Ϫ MEFs (Fig. 2B ). These data demonstrated that the ability of MyoD to transactivate is significantly diminished in the absence of SRC1A and that SRC1A is essential for certain types of muscle specific gene expression.
NH 2 Terminus of MyoD Is Targeted by p160
Coregulators in Vitro-We tested the ability of MyoD protein to interact in vitro with all three classes of p160s using GST-affinity binding assays (Fig. 3B) . In vitro translated 35 S-labeled GRIP1 (lane 1), SRC1A (lane 4), and p/CIP proteins (lane 7) all bind to GSTMyoD significantly when compared with GST alone (lanes 2, 5, and 8). These data establish that the three classes of p160 coregulators can bind directly to MyoD in vitro.
The NH 2 terminus of MyoD functions as an activating domain (33) , and its bHLH domain is essential for both heterodimerizing with E proteins (34) and DNA binding (35, 36) . These domains, or MyoD deleted for these domains, were cloned into GST fusion vectors (Fig. 3A) . GST affinity assays reveal that the NH 2 -terminal domain of MyoD is both required and sufficient to interact fully with any of the three p160 coregulators and with p300 (Fig. 3, C and D) , whereas deletion of the MyoD bHLH domain does not significantly effect its ability to bind (Fig. 3E ). However, when tested alone (Fig. 3F) , the bHLH domain retained minimal ability to interact with p/CIP greater than the binding to GST alone. On the other hand, the COOH terminus of MyoD does not appear to be involved in interactions with p300 or with SRC1A and GRIP1 although p/CIP may require it for full binding activity to some extent (Fig. 3G) . Taken together, these data suggest that the NH 2 terminus of MyoD is the segment of MyoD that primarily interacts with the p160 coregulators and with p300.
p160 Coregulators Associate with MyoD in Vivo-Mammalian two-hybrid assays were used next to determone whether these in vitro interactions between p160 coregulators and MyoD also can occur in cells. Full-length GRIP1 and p/CIP were fused to the GAL4-DNA binding domain to generate GAL-GRIP1 and GALCIP; SRC1A was fused to the LexA-DNA binding domain to generate LexASRC1A. These constructs were individually tested for their ability to effect the transcriptional activity of VP16MyoD. As reported previously (37, 38) , GAL-GRIP1, LexASRC1A, and GALCIP can themselves contribute substantially to reporter activity (column 2 of Fig. 4, A-C) . Significantly, all reporter activities were increased in a dose dependent manner when cotransfected with VP16MyoD (columns 3-5 of Fig. 4, A-C) . each of the p160s that interact with MyoD both in vitro and in vivo (32) . Two separated short domains in the middle of each p160 (designated as MID1 and MID2) as well as the C termini appear to be crucial MyoD interaction domains. We have synthesized in vitro and in vivo the proteins encoded by mutant constructs that lack these elements (designated as ⌬(MID1/ 2ϩC). Significantly all these mutant proteins lose the ability to interact with MyoD both in vitro and vivo (32) . We have now tested these constructs to determine whether the essential interaction domains also play functional roles in regulating the effects of the p160s on MyoD-mediated transcription. Indeed, the mutant constructs all lose their effects on MyoD-mediated expression (Fig. 5, A-C) . SRC1A and p/CIP ⌬(MID1/2ϩC) mutants totally lose their ability to augment MyoD-mediated expression on the 4RE, MCK, and HCA reporter constructs (Fig.  5, A and B) . Most notably, the GRIP1 mutant loses its suppressive effects and is associated with an intriguing increase in the transcriptional activity of MyoD (Fig. 5C) . Thus the functional effects of the p160 coregulators on MyoD mediated transcription, as well as their protein-protein interactions with MyoD, N in the figure) . E, GST affinity binding assays were carried out as shown in B with GST-MyoD-⌬bHLH (indicated as ⌬bHLH in the figure). F, GST affinity binding assays were carried out as shown in B with GST-MyoD-bHLH (indicated as bHLH in the figure) . G, GST affinity binding assays were carried out as shown in B with GST-MyoD-⌬C (indicated as ⌬C in the figure).
requires the presence of a combination of the MID1, MID2, and COOH-terminal segments. This is consistent with the idea that these functional effects, whether activating or suppressing gene expression, require direct p160-MyoD physical interaction. p300 and the p160 Coregulators Bind to Different Subdomains of the MyoD Amino Terminus-The NH 2 terminus domain of MyoD is activated by the binding there of p300/CBP (26 -28) involving an FYD motif and phenylalanine 42. When these sites are mutated, the NH 2 terminus loses its ability to transactivate or to bind and be coactivated by p300 (26 -28) . We speculated that the differential effects of the p160s on MyoD activity might be related to their distinctive contacts with the activation domain and with the p300/CBP binding sites.
To begin to test this possibility, we evaluated the GST binding affinity of p300 and of the p160s for three subsegments (and their deletions) of the MyoD NH 2 -terminal region designated in Fig. 6A as N1 (aa 1-36 ), N2 (aa 37-72), and N3 (aa 73-109). We tested as well a MyoD NH 2 terminus bearing a mutation (F-P) at the critical residue 42. Consistent with previous results (26 -28) it appears that both the N3 and N2 regions, including wild type residue 42, are involved in full binding of p300 to the MyoD activation domain (Fig. 6B ). As shown in Fig. 6 , C-E, the N1 subsegment of MyoD is neither required nor capable of interacting with GRIP1, SRC1A, or p/CIP. The N2 region binds to GRIP1 and SRC1A but not p/CIP. The N3 subsegment appears to interact with both GRIP1 and p/CIP but not SRC1A. Also of importance is the discovery that whereas binding of SRC1A and p/CIP are unaffected by mutation of MyoD at residue 42, both p300 and GRIP1 binding is reduced (lane 7 in Fig. 6, B-E) . These results suggest that SRC1A and p/CIP each interact with two different amino acid subsets of the NH 2 -terminal activation domain of MyoD. The binding targets of GRIP1 could well overlap those of both SRC1A and p/CIP.
The functional repression of MyoD activated transcription by GRIP1 stands in stark contrast to the coactivation properties of p300, p/CIP, and SRC1A. That GRIP1, the (co)repressor, binds to the activation domain of MyoD at regions that fully overlap those required for binding by the coactivators p300, SRC1A, and p/CIP has not escaped our attention. Whereas the precise mechanisms of these effects remain to be established, it is attractive to speculate that SRC1A and p/CIP can positively effect the simultaneous interactions of the MyoD activation domain with p300 and pCAF. Conversely, the overlap of the GRIP1 binding sites on MyoD with those of p300, SRC1A, and p/CIP suggest that an interference mechanism may explain the repression effects of GRIP1.
The HAT Domain of SRC1A Is Required to Coactivate MyoD-A histone acetyltransferase (HAT) activity has been demonstrated in both SRC1A and ACTR (human homologue of p/CIP) (18, 25) . It is also known that the HAT domain of pCAF is required to coactivate MyoD-dependent transcription (27) . We tested whether this HAT activity of SRC1A was essential for its coactivation of MyoD-activated transcription. The full HAT activity of SRC1A has been located at its COOH terminus (aa 1107-1441) (25) . Thus, SRC1A⌬C, a mutant devoid of its COOH terminus (aa 1105-1441), was initially employed to test this hypothesis. As shown in Fig. 7A , it appeared that the coactivation ability of the SRC1A mutant devoid of its HAT domain (lanes 6 -8) is greatly diminished compared with wild type SRC1A (lanes 3-5) . The importance of the HAT domain was further confirmed by testing its effect on MyoD-mediated transcription. We cotransfected a segment of SRC1A (encoding amino acids 1028 -1441) carrying both the MID2 region and the HAT COOH-terminal domain. This segment potentiated transcription from the MyoD activated MCK promoter. (Fig. 7B,  lane 5 and 6) . The HAT domain of SRC1A thus appears to be required for MyoD-dependent transcription since it is embedded in the MID2ϩCOOH-terminal domain tested above.
DISCUSSION
Our examination of the effects of p160 proteins not only demonstrates their functions in modulating MyoD-dependent muscle specific gene expression but reveals their independent and different roles in regulating the same transcriptional activator, MyoD. We found that SRC1A and p/CIP are capable of potentiating MyoD transactivation in C3H10T1/2 cells. We observed increases by SRC1A of up to 9-fold and 4-fold by p/CIP using the natural HCA promoter in pluripotent 10T1/2 cells (Fig. 1C) . Thus, we concluded that both SRC1A and p/CIP function as coactivators for MyoD-dependent transcription, activities completely consistent with their known positive effects on other transcription factors.
In marked contrast, GRIP1, which has been extensively characterized as a coactivator of ligand-mediated nuclear hormone receptor-dependent transcription, significantly downregulates MyoD-reporter activity on both 4RE and MCK promoters. It does this not only in 10T1/2 cells but in differentiating myoblasts as well (32) by at least 80 -100% when compared with MyoD tested alone. The extent of such negative regulation is less extreme on the HCA promoter, but it reduces MyoD transactivation by 40 -50%. This appears to be the first report in which any p160 protein acts as a repressor of a transcription factor. Our observations are operationally quite different from the one reported instance in which a p160 protein was discovered to repress transcription (39) . In that paper it was shown that the glucocorticoid receptor (GR) repressed transcription of the collagenase promoter (col3A) and that GRIP1, binding to the GR, further suppressed transcription. Thus GRIP1, by increasing the already negative activity of GR, was acting to enhance GR activity. In the case of the transcriptional activator MyoD, GRIP1 works to oppose its activity.
Chen et al. (40) have analyzed extensively the effects of GRIP1 on transcription mediated by the other major class of myogenic transactivators, MEF2. When transcription is dependent on the presence of MEF2, GRIP1 strongly enhances transcription from many of the same promoters we have tested (40) . MEF2 contributes to E-box-dependent transcription by binding to MyoD and helping tether other coactivators including p300/CBP and, as shown by Chen et al. (40) , GRIP1. Indeed, among the experimental paradigms tested by Chen et al. (40) , they concluded that GRIP1 had no effect on transcription from MyoD dependent promoters in the absence of MEF2. However, a review of their data indeed shows that in the absence of MEF2 GRIP1 suppresses transcription mediated by MyoD family members on both the MCK promoter and on the artificial E-box promoter, 4RE.
MyoD transactivation is significantly decreased on both 4RE and HCA promoters in SRC1AϪ/Ϫ MEFs, suggesting that SRC1A is required for full MyoD transactivation (Fig. 2, A and  C) . The transactivation activity of both GALMyoD (full-length of MyoD fused to Gal-DBD, 4-fold decreased) and GALMyoD-N (NH 2 -terminal activation domain of MyoD fused to Gal-DBD, 2-fold decreased) was also decreased using a G4TATALUC reporter in SRC1AϪ/Ϫ MEFs when compared with wild type MEFs (data not shown). In addition, SRC1A appears to be essential for MyoD transactivation activity on the MCK promoter in SRC1AϪ/Ϫ MEFs (Fig. 2B) . The mechanisms by which MyoD acts differently on various muscle specific promoters in SRC1AϪ/Ϫ MEFs still remains to be investigated.
MyoD is active only when it is acetylated (27, 29) . The HAT activity of either pCAF (27, 29) or p300 (32) can acetylate MyoD. However, it is the HAT activity of pCAF but not that of p300/CBP that is required to coactivate MyoD-dependent transcription (27) . Given that 1) the in vitro interactions between MyoD and pCAF are much weaker than between MyoD and p300 and 2) there is no detectable interaction between pCAF and MyoD in mammalian two-hybrid assays, it seems likely that the role of pCAF in MyoD-activated transcription must be mediated by other associated factors. To date it has been concluded that p300/CBP plays that role (27) . We have shown here that in addition to p300/CBP, all p160 coregulators are able to associate with MyoD in vivo (Fig. 4) . Thus, it is possible that two p160s, SRC1A and p/CIP, and p300/CBP, either together or individually, may stablize the interactions required to complex pCAF and its acetylation activity with MyoD. Further support for this notion is provided by the observation that E1A, a direct inhibitor of myogenesis and MyoD-dependent gene transcription targets p160s. 3 The important role of p160 in the function of such myogenic coactivator complexes is underscored by our discovery of the direct physical interactions between p160 co-3 H-Y. Wu, unpublished data. 35 S-labeled p300 was incubated with various GST-MyoD-NH 2 -terminal segments immobilized on glutathione-agarose beads. The bound proteins were eluted and resolved by autoradiography after SDS-PAGE. Glutathione-agarose-immobilized GST protein serves as control. 10% Input indicates that the lane was loaded with 10% of the amount in vitro translated p160 product that was used in the binding reaction. C, GST affinity binding assays were carried out as shown in E with GRIP1. D, GST affinity binding assays were carried out as shown in E with SRC1A. E, GST affinity binding assays were carried out as shown in E with CIP.
regulators and MyoD in vitro (Fig. 3) . Importantly, these physical interactions between p160s and MyoD are able to take place independently of both E2A gene products, the heterodimer partners of myogenic bHLH proteins, and MEF2, since they are not necessarily included in the in vitro GST binding reactions.
The activation domains of transcription factors are the binding targets of co-activating adaptor proteins such as p300/CBP. SRC1A and p/CIP coactivators follow this rule, since they bind to the NH 2 -terminal activation domain of MyoD (Fig. 3, C and  D) . p300, SRC1A, and p/CIP all coactivate MyoD-dependent transcription through interactions at the same NH 2 -terminal activation domain of MyoD. This raises the question of whether their binding is coordinated and cooperative or whether their binding activities and docking sites are mutually interchangeable. Our experiments suggest that each has its individual binding positions on the NH 2 terminus of MyoD (Fig. 6) . Thus, it is likely that these molecules interact and regulate MyoD transactivation in a coordinated manner rather than competing for binding. GRIP1 appears to be an exception since it binds throughout the NH 2 terminus (Fig. 6C ). This suggests that it could compete for binding by the coactivators thus providing a logical and testable explanation for the (co)repressor activity of GRIP1 on MyoD-mediated transcription.
MyoD protein must be acetylated to function as a transcriptional activator. The HAT domains of both p300 and PCAF are capable of acetylating MyoD. However, only the HAT domain of PCAF, which binds to the MyoD transcription complex mostly through its affinity for p300, is essential (27, 29) . SRC1A and pCIP contain HAT domains (25) and the HAT activities of these domains might possibly play a positive regulatory role in MyoD activity (Fig. 7) . In that regard, GRIP1 has no known HAT activity. Indeed, if GRIP1 binding to the MyoD NH 2 terminus displaces p300/CBP and SRC1A and p/CIP, there would then be no known HAT domain bound strongly to MyoD. Accordingly, MyoD would then remain in an unacetylated and, hence, inactive state. Experiments to directly assess these possibilities are in progress.
